Zoetis Inc. $ZTS Shares Sold by S&CO Inc.

S&CO Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 14.7% in the 2nd quarter, Holdings Channel reports. The firm owned 9,696 shares of the company’s stock after selling 1,674 shares during the period. S&CO Inc.’s holdings in Zoetis were worth $1,512,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Nuveen LLC purchased a new stake in Zoetis during the 1st quarter worth approximately $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after acquiring an additional 1,995,491 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after acquiring an additional 1,782,110 shares during the last quarter. Polen Capital Management LLC increased its position in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Finally, Amundi increased its position in shares of Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company’s stock worth $575,691,000 after purchasing an additional 846,909 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.5%

Shares of ZTS opened at $120.20 on Monday. Zoetis Inc. has a 12-month low of $117.26 and a 12-month high of $181.85. The firm has a market capitalization of $52.97 billion, a P/E ratio of 20.69, a P/E/G ratio of 2.31 and a beta of 0.90. The firm has a 50-day moving average price of $144.21 and a 200 day moving average price of $152.63. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio is currently 33.67%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Argus reissued a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $191.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.